GIA632

**GIA632** is an investigational **monoclonal antibody** targeting **IL-15** developed by **Novartis** for the treatment of moderate to severe **atopic dermatitis**. It functions by inhibiting IL-15 signaling, a key cytokine pathway driving T-cell activation and inflammation in autoimmune skin diseases, potentially offering targeted relief with improved efficacy and tolerability over conventional therapies like topical corticosteroids. Currently in **Phase 2a** clinical development, GIA632 is being evaluated in a randomized, placebo-controlled trial (NCT07220577) assessing efficacy via IGA response at week 16, alongside safety and tolerability in adults with longstanding atopic dermatitis.[1][2][3][5]

Other names

GIA-632GIA632GIA 632